Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 2Meningeal Carcinomatosis 2Medulloblastoma 2Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Ependymoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 25Magnetic Resonance Spectroscopy 19Etoposide 14Cyclophosphamide 13Radiotherapy 10Filgrastim 10Bevacizumab 10Carboplatin 9Biopsy 8Cisplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Carmustine 6Radiation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Erlotinib Hydrochloride 4Azacitidine 4olaparib 3etoposide phosphate 3Surgical Procedures, Operative 3Lapatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ependymoma × omburtamab I-131 × Clear all
NCT04743661 2026-02-05

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Pediatric Brain Tumor Consortium

Phase 2 Active not recruiting
62 enrolled
CNS

Ependymoma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡